TherapeuticsMD, Inc.
TXMD
$1.15
$0.010.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.25% | -97.70% | -98.57% | -98.28% | -98.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.25% | -97.70% | -98.57% | -98.28% | -98.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 35.25% | -97.70% | -98.57% | -98.26% | -98.10% |
| SG&A Expenses | -46.71% | -69.94% | -81.53% | -83.02% | -84.30% |
| Depreciation & Amortization | -44.79% | 76.09% | 46.54% | 15.38% | -22.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.53% | -65.22% | -78.74% | -81.29% | -83.43% |
| Operating Income | 59.03% | -109.39% | -114.91% | -127.05% | -179.93% |
| Income Before Tax | 69.74% | -109.48% | -116.76% | -137.51% | -820.86% |
| Income Tax Expenses | 27.91% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.97% | -109.38% | -116.61% | -137.25% | -816.85% |
| Earnings from Discontinued Operations | 105.08% | -97.50% | -109.18% | -100.86% | -102.33% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.78% | -104.85% | -114.24% | -104.71% | -109.18% |
| EBIT | 59.03% | -109.39% | -114.91% | -127.05% | -179.93% |
| EBITDA | 63.10% | -108.20% | -113.10% | -124.11% | -168.19% |
| EPS Basic | 81.12% | -104.00% | -112.41% | -103.97% | -108.20% |
| Normalized Basic EPS | 58.71% | -106.41% | -110.79% | -122.51% | -199.43% |
| EPS Diluted | 81.25% | -104.73% | -116.25% | -104.26% | -109.05% |
| Normalized Diluted EPS | 58.71% | -107.44% | -113.29% | -131.89% | -9,672.92% |
| Average Basic Shares Outstanding | 10.58% | 13.65% | 15.73% | 16.77% | 15.53% |
| Average Diluted Shares Outstanding | 10.58% | 9.95% | 11.83% | 12.68% | 11.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |